Bone Cancer Trial Results
Denosumab Keeps Bones Strong during Prostate Cancer Treatment
(Posted: 10/28/2009) - Treatment with the monoclonal antibody denosumab increased bone mineral density (BMD) and reduced the risk of fractures in men who received a common treatment for prostate cancer that had not spread to other parts of the body, according to the results of a large, placebo-controlled clinical trial published in the August 20, 2009, New England Journal of Medicine.
Experimental Drug for Osteosarcoma Improves Overall Survival
(Posted: 03/04/2008) - Patients with osteosarcoma who received the experimental drug mifamurtide (L-MTP-PE) along with chemotherapy fared better than patients who received chemotherapy alone, according to the Feb. 1, 2008, Journal of Clinical Oncology.
(Posted: 10/28/2009) - Treatment with the monoclonal antibody denosumab increased bone mineral density (BMD) and reduced the risk of fractures in men who received a common treatment for prostate cancer that had not spread to other parts of the body, according to the results of a large, placebo-controlled clinical trial published in the August 20, 2009, New England Journal of Medicine.
Experimental Drug for Osteosarcoma Improves Overall Survival
(Posted: 03/04/2008) - Patients with osteosarcoma who received the experimental drug mifamurtide (L-MTP-PE) along with chemotherapy fared better than patients who received chemotherapy alone, according to the Feb. 1, 2008, Journal of Clinical Oncology.
